Intracellular delivery of anti-kras antibodies formulated into nanocapsules

Abstract

Provided herein is a composition, comprising: a plurality of nanoentities comprising an inner core surrounded by an outer shell, the outer shell comprising a polymer, the inner core comprising at least one hydrophobic compound, wherein the nanoentities comprise a pharmaceutical agent, wherein the pharmaceutical agent is an antibody or a fragment thereof, wherein the antibody or the fragment thereof binds to an epitope of an activated mutated KRAS protein. These anti-KRAS antibodies formulated into particular nanoentities are able to be intracellular delivered and further, are able to perform their biological activity inside the cell, thus being useful in the treatment of cancer and other disease associated with a mutation in a KRAS gene.

Dependencies are inferred from the claim text.